Best Biotech Stocks For 2019

tags:VYGR,AGEN,CBM,

As with most small biotechs, VBI Vaccines (VBIV) trades in a volatile manner. The stock now trades some 35% from the yearly highs of $6.60 despite some promising developments for the stock during June.

My last research at the end of February highlighted the hidden opportunity in the hepatitis B opportunity. The question now is whether an investor gets another opportunity to buy VBI Vaccines at $4.30?

Phase 3 Catalyst

Best Biotech Stocks For 2019: Voyager Therapeutics, Inc.(VYGR)

Advisors' Opinion:

• [By Trey Thoelcke]

  Voyager Therapeutics Inc. (NASDAQ: VYGR) also saw a director at the buy window last week. At an average of $18.31 apiece, the 3,000 shares reportedly acquired cost that director less than $55,000. Here too, a disappointing earnings report had shares down, offering an entry point. The stock was last seen up more than 12% from the purchase price, so seemingly a well-timed buy.

• [By Max Byerly]

  Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Max Byerly]

  Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Chris Lange]

  Voyager Therapeutics Inc. (NASDAQ: VYGR) will be presenting at the American Society of Gene and Cell Therapy annual meeting taking place May 16 to 19, 2018, in Chicago. The firm will be releasing data from its lead clinical program for Parkinson's disease, its preclinical programs targeting a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Huntington's disease and Friedreich's ataxia, and its gene therapy vector platform including novel adeno-associated virus capsid optimization efforts and manufacturing capabilities.

• [By Lisa Levin] Gainers The Trade Desk, Inc. (NASDAQ: TTD) jumped 36.2 percent to $71.82 after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance. WideOpenWest, Inc. (NYSE: WOW) jumped 30.4 percent to $8.80 after the company reported Q1 results. MoSys, Inc. (NASDAQ: MOSY) shares surged 28.6 percent to $1.9541 after the company reported better-than-expected Q1 results and issued strong Q2 forecast. Boxlight Corporation (NASDAQ: BOXL) gained 24 percent to $6.39. Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares gained 19.1 percent to $24.60. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee, which met to discuss the safety and efficacy of subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome, voted 12-8 to support its approval. Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 17 percent to $10.31 after reporting Q3 results. ArcBest Corporation (NASDAQ: ARCB) gained 16.8 percent to $43.1457 after reporting upbeat quarterly earnings. Amtech Systems, Inc. (NASDAQ: ASYS) rose 16.2 percent to $8.60. Amtech posted Q2 earnings of $0.19 per share on sales of $32.783 million. Identiv, Inc (NASDAQ: INVE) surged 14.4 percent to $3.8450 following Q1 results. Omeros Corporation (NASDAQ: OMER) shares rose 14.3 percent to $18.43 following Q1 results. VivoPower International PLC (NASDAQ: VVPR) gained 11.5 percent to $2.71. Intersections Inc. (NASDAQ: INTX) gained 11.4 percent to $2.55 after reporting Q1 results. Noodles & Company (NASDAQ: NDLS) shares rose 10.9 percent to $8.65 following Q1 results. Voyager Therapeutics, Inc. (NASDAQ: VYGR) climbed 10.6 percent to $18.54 following Q1 results. Blink Charging Co. (NASDAQ: BLNK) rose 10.4 percent to $5.739. Immersion Corporation (NASDAQ: IMMR) gained 9.6 percent to $12.69
• [By Chris Lange]

  For many drug developers, Parkinson's disease is a tricky disease to treat. However, developing a treatment ultimately could yield a huge reward as there are currently no therapies that effectively slow or reverse the progression of this disease. And after Thursday's announcement, Voyager Therapeutics Inc. (NASDAQ: VYGR) could be poised to reap this reward.

Best Biotech Stocks For 2019: Agenus Inc.(AGEN)

Advisors' Opinion:

• [By George Budwell]

  The small-cap immuno-oncology company Agenus (NASDAQ:AGEN) and the inhaled insulin company MannKind Corporation (NASDAQ:MNKD) are prime examples of this phenomenon. Even though both of these companies have been in existence for over two decades, these two particular biotechs have failed to bring a product to market capable of generating a significant revenue stream. As a result, these two companies have essentially been forced to wipe out their early shareholders through serial dilution.

• [By George Budwell]

  Shares of the small-cap biotech Agenus (NASDAQ:AGEN) reversed its year-long down trend by gaining a stately 20.1% last month, according to data from S&P Global Market Intelligence. What sparked this marked turnaround?

• [By George Budwell]

  Agenus (NASDAQ:AGEN), a small-cap cancer immunotherapy and vaccine company, has started to claw its way back from a steep downturn that began last April. Specifically, the drugmaker's shares have spiked by a healthy 29% over just the past three trading sessions. 

Best Biotech Stocks For 2019: Cambrex Corporation(CBM)

Advisors' Opinion:

• [By George Budwell, Chuck Saletta, and Todd Campbell]

  So, with the biotech space solidly on the comeback trail, we asked three of our Motley Fool contributors which stocks they think are poised to keep churning higher in February and perhaps for the remainder of the year. They suggested Viking Therapeutics (NASDAQ:VKTX), Cambrex (NYSE:CBM), and Sarepta Therapeutics (NASDAQ:SRPT). Here's why.     

• [By Brian Feroldi]

  In response to reporting of fourth-quarter and full-year quarterly results, shares of Cambrex Corporation (NYSE:CBM), a supplier to the life sciences industry, fell 11% as of 11:10 a.m. EST on Wednesday.

• [By Logan Wallace]

  Shares of Cambrex Co. (NYSE:CBM) have earned a consensus recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $60.00.

• [By Money Morning Staff Reports]

  Cambrex Corp. (NYSE: CBM) was founded in 1981 and is a leading supplier of generic active pharmaceutical ingredients (APIs).

  Cambrex has more than 100 generic APIs, and 90 of them are commercially sold.